Clinical Trial Detail

NCT ID NCT02893917
Title Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate adenocarcinoma

Therapies

Cediranib + Olaparib

Olaparib

Age Groups: adult senior

No variant requirements are available.